Meeder Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Meeder Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-25	Closed	-$4K	–	2547
2021 Q2	$4K	Buy	25 +13	+108%	+$2K	﹤0.01%	2014
2021 Q1	$2K	Hold	12	–	–	﹤0.01%	2080
2020 Q4	$2K	Buy	12 +6	+100%	+$857	﹤0.01%	1488
2020 Q3	$1K	Buy	+6	New	+$814	﹤0.01%	1988
2020 Q2	–	Sell	-3	Closed	–	–	2235
2020 Q1	$0	Sell	3 -10	-77%	-$1.15K	﹤0.01%	2405
2019 Q4	$2K	Hold	13	–	–	﹤0.01%	2015
2019 Q3	$1K	Buy	+13	New	+$1.36K	﹤0.01%	2062

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Meeder Asset Management's IBB Position: Q3 2021 in Review

Meeder Asset Management sold out of iShares Biotechnology ETF (IBB) in Q3 2021, closing a stake of 25 shares — an estimated $4K sold.

Meeder Asset Management first reported a position in IBB in Q3 2019 and held it in 7 quarters. The position peaked at $4K in Q2 2021. 855 funds tracked by Wall St. Rank hold IBB as of Q3 2021.

Meeder Asset Management reported no remaining iShares Biotechnology ETF position as of Q3 2021 after selling out during the quarter.
Meeder Asset Management sold 25 iShares Biotechnology ETF shares in Q3 2021, an estimated $4K.
Meeder Asset Management first reported a position in iShares Biotechnology ETF in Q3 2019 and held it in 7 quarters.
Meeder Asset Management's iShares Biotechnology ETF position peaked at $4K in Q2 2021.
855 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2021.

Based on Meeder Asset Management's 13F filing for Q3 2021, filed 8 Nov 2021.